Grifols' Chronos Platform Detects Parkinson's Disease Biomarkers Up to 12 Years Before Clinical Diagnosis
核心洞察
Grifols' Chronos-PD platform identified biological changes associated with Parkinson's disease occurring up to 12 years before clinical diagnosis using advanced proteomics and AI analysis.
The proof-of-concept study analyzed over 2,600 longitudinal plasma samples and measured over 25,000 protein types, making it the most deeply profiled longitudinal proteomic study in Parkinson's disease to date.
Researchers discovered novel early biomarkers including modulation of the CXCL12 (搜索)-cell adhesion molecules-integrin (搜索) axis, which governs blood-brain barrier integrity and neuroinflammation in Parkinson's disease.
Grifols has unveiled groundbreaking proof-of-concept data from its Chronos-PD platform demonstrating that biological changes associated with Parkinson's disease can be detected up to 12 years before clinical diagnosis. The findings, presented at the AD/PD 2026 conference in Copenhagen and published in medRxiv, represent a significant advancement in early disease detection that could transform therapeutic intervention strategies.
The pioneering program, driven by Grifols' subsidiary Alkahest (搜索) and funded by the Michael J. Fox Foundation (搜索) for Parkinson's Research, analyzed over 2,600 longitudinal plasma samples from rigorously matched Parkinson's disease cases and controls. Using four complementary proteomics platforms, researchers measured over 25,000 protein types, creating the most deeply profiled longitudinal proteomic study in Parkinson's disease to date.
Novel Biomarker Discovery and Validation
The study tracked plasma protein evolution over time in people with Parkinson's disease, covering periods up to 12 years before diagnosis and 9 years after. This longitudinal approach enabled researchers to establish an early-warning system for disease emergence and identify reproducible early biomarkers validated across up to 5 independent cohorts.
Among the key discoveries was the identification of novel early biomarkers, including major modulation of the CXCL12 (搜索)-cell adhesion molecules-integrin (搜索) axis. This signaling network governs leukocyte trafficking and blood-brain barrier integrity and is implicated in Parkinson's disease-associated neuroinflammation.
"This new proof-of-concept data offers additional insights into the biology and progression of PD, years before clinical detection," said Dr. Jörg Schüttrumpf, Grifols Chief Scientific Innovation Officer. "Going back in time to search for the earliest signs of disease can help accelerate and ultimately develop new diagnostics and disease-modifying therapeutics."
Addressing Critical Unmet Medical Need
Parkinson's disease affects nearly 1 million people in the United States and more than 6 million people worldwide. The disorder occurs when brain cells that produce dopamine, a chemical that coordinates movement, stop working or die. Currently, physicians rely on medical history, physical examination, and brain imaging tests for diagnosis, but by the time the disorder is detected, it is often too late to slow progression or reverse damage.
"Despite decades of research and treatment advancement, the understanding of the drivers of the disease remains limited," Schüttrumpf noted. This leaves early detection biomarkers as one of the most urgent needs for therapeutic interventions to halt or reverse the disease before irreversible damage occurs.
Platform Scalability and Future Applications
The Chronos platform leverages Grifols' repository of more than 100 million plasma samples collected over nearly 15 years, representing one of the world's largest collections of biospecimens. This proprietary bank contains plasma representing thousands of disease states connected to real-world health data, enabling the same analytical approaches used for Parkinson's disease to be replicated across multiple therapeutic areas.
"Chronos reframes early disease detection by shifting from symptom-based evaluation to molecular trajectory profiling, offering a powerful foundation for accelerating the development of early detection and intervention tools at population scale," said Benoit Lehallier, PhD, Principal Investigator of Chronos and Senior Director of Data Science at Alkahest (搜索).
The platform combines artificial intelligence, advanced proteomics, and real-world data to identify biomarkers that could help predict disease risk and guide future treatments. The validation of the Chronos platform through the Parkinson's disease study demonstrates its potential applications beyond neurological disorders, supporting Grifols' vision of addressing some of the world's most pressing public health challenges through early disease detection and intervention.